NMRA
Neumora Therapeutics Inc (NMRA)
Healthcare • NASDAQ • $1.83-5.67%
- Symbol
- NMRA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.83
- Daily Change
- -5.67%
- Market Cap
- $339.07M
- Trailing P/E
- N/A
- Forward P/E
- -2.04
- 52W High
- $3.65
- 52W Low
- $0.61
- Analyst Target
- $8.91
- Dividend Yield
- N/A
- Beta
- 3.05
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the trea…
Company websiteResearch NMRA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.